[go: up one dir, main page]

HUS2400045I1 - Delgocitinib alkalmazása krónikus kézekcéma kezelésére - Google Patents

Delgocitinib alkalmazása krónikus kézekcéma kezelésére

Info

Publication number
HUS2400045I1
HUS2400045I1 HUS2400045C HUS2400045C HUS2400045I1 HU S2400045 I1 HUS2400045 I1 HU S2400045I1 HU S2400045 C HUS2400045 C HU S2400045C HU S2400045 C HUS2400045 C HU S2400045C HU S2400045 I1 HUS2400045 I1 HU S2400045I1
Authority
HU
Hungary
Prior art keywords
delgocitinib
treatment
hand eczema
chronic hand
chronic
Prior art date
Application number
HUS2400045C
Other languages
English (en)
Original Assignee
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55236207&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUS2400045(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Leo Pharma As filed Critical Leo Pharma As
Publication of HUS2400045I1 publication Critical patent/HUS2400045I1/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Storage Of Fruits Or Vegetables (AREA)
HUS2400045C 2016-01-21 2024-12-17 Delgocitinib alkalmazása krónikus kézekcéma kezelésére HUS2400045I1 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16152215 2016-01-21
EP17701828.0A EP3405197B1 (en) 2016-01-21 2017-01-20 Use of delgocitinib for the treatment of chronic hand eczema

Publications (1)

Publication Number Publication Date
HUS2400045I1 true HUS2400045I1 (hu) 2025-01-28

Family

ID=55236207

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE17701828A HUE064192T2 (hu) 2016-01-21 2017-01-20 Delgocitinib alkalmazása krónikus kézekcéma kezelésére
HUS2400045C HUS2400045I1 (hu) 2016-01-21 2024-12-17 Delgocitinib alkalmazása krónikus kézekcéma kezelésére

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE17701828A HUE064192T2 (hu) 2016-01-21 2017-01-20 Delgocitinib alkalmazása krónikus kézekcéma kezelésére

Country Status (30)

Country Link
US (2) US20200397787A1 (hu)
EP (2) EP3405197B1 (hu)
JP (1) JP6929860B2 (hu)
KR (2) KR20180102662A (hu)
CN (3) CN117159554A (hu)
AU (3) AU2017209932A1 (hu)
BR (1) BR112018014769A2 (hu)
CA (1) CA3010547A1 (hu)
DK (1) DK3405197T3 (hu)
ES (1) ES2963784T3 (hu)
FI (2) FI3405197T3 (hu)
FR (1) FR24C1053I2 (hu)
HR (1) HRP20231448T1 (hu)
HU (2) HUE064192T2 (hu)
IL (4) IL297379A (hu)
LT (2) LT3405197T (hu)
MX (2) MX394358B (hu)
NL (1) NL301306I2 (hu)
NO (1) NO2024058I1 (hu)
PL (1) PL3405197T3 (hu)
PT (1) PT3405197T (hu)
RS (1) RS64798B1 (hu)
RU (1) RU2018130097A (hu)
SG (2) SG10202006830WA (hu)
SI (1) SI3405197T1 (hu)
SM (1) SMT202300415T1 (hu)
TW (2) TWI783921B (hu)
UA (1) UA123780C2 (hu)
WO (1) WO2017125523A1 (hu)
ZA (1) ZA201804098B (hu)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202110777XA (en) * 2019-05-15 2021-11-29 Leo Pharma As Treatment of cutaneous lupus erythematosus
US20250082638A1 (en) * 2021-02-02 2025-03-13 Pfizer Inc. Dosing Regime For Treatment of Chronic Hand Eczema
US20250041304A1 (en) * 2021-07-30 2025-02-06 Eli Lilly And Company Treatment of Hand Eczema with Baricitinib
EP4680246A1 (en) 2023-03-17 2026-01-21 LEO Pharma A/S A method for the treatment of chronic hand eczema in patients with moderate to severe chronic hand eczema

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI466885B (zh) 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
US20130302298A1 (en) * 2010-11-30 2013-11-14 Bio-K Plus International Inc. Treatment and prevention of eczema
US20140343034A1 (en) * 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent

Also Published As

Publication number Publication date
AU2022252766B2 (en) 2024-08-29
FR24C1053I1 (fr) 2025-02-21
FR24C1053I2 (fr) 2025-12-05
NL301306I2 (nl) 2024-12-30
SMT202300415T1 (it) 2024-01-10
EP4257205A2 (en) 2023-10-11
SG11201805394QA (en) 2018-08-30
ZA201804098B (en) 2024-10-30
AU2017209932A1 (en) 2018-07-05
IL260094A (en) 2018-07-31
RU2018130097A3 (hu) 2020-05-25
NZ743582A (en) 2024-12-20
UA123780C2 (uk) 2021-06-02
MX2022005915A (es) 2022-06-27
MX394358B (es) 2025-03-24
LTPA2024538I1 (hu) 2025-01-10
BR112018014769A2 (pt) 2018-12-11
IL313543A (en) 2024-08-01
ES2963784T3 (es) 2024-04-02
IL320757A (en) 2025-07-01
CN117159553A (zh) 2023-12-05
RS64798B1 (sr) 2023-11-30
FIC20240048I1 (fi) 2024-12-19
RU2018130097A (ru) 2020-02-21
TWI783921B (zh) 2022-11-21
SG10202006830WA (en) 2020-08-28
MX2018008449A (es) 2018-08-09
SI3405197T1 (sl) 2024-03-29
HUE064192T2 (hu) 2024-02-28
CN117159554A (zh) 2023-12-05
WO2017125523A1 (en) 2017-07-27
JP6929860B2 (ja) 2021-09-01
DK3405197T3 (da) 2023-11-27
US20230138114A1 (en) 2023-05-04
NO2024058I1 (no) 2024-12-13
HRP20231448T1 (hr) 2024-03-01
CN108472297A (zh) 2018-08-31
KR20180102662A (ko) 2018-09-17
EP4257205A3 (en) 2023-12-20
TW201736382A (zh) 2017-10-16
US20200397787A1 (en) 2020-12-24
JP2019502734A (ja) 2019-01-31
KR20250088666A (ko) 2025-06-17
EP3405197B1 (en) 2023-09-06
IL297379A (en) 2022-12-01
PL3405197T3 (pl) 2024-02-12
PT3405197T (pt) 2023-12-06
LT3405197T (lt) 2023-11-27
AU2024266962A1 (en) 2024-12-19
TW202332451A (zh) 2023-08-16
CA3010547A1 (en) 2017-07-27
EP3405197A1 (en) 2018-11-28
FI3405197T3 (fi) 2023-11-23
TWI841027B (zh) 2024-05-01
AU2022252766A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
PL3504187T3 (pl) Stosowanie pridopidyny w leczeniu zaburzeń czynnościowych
IL259996A (en) Combinations for cancer treatment
LT3122358T (lt) Egfr ir cmet inhibitorių deriniai, skirti vėžio gydymui
PT3261726T (pt) Composição para o tratamento do acne
IL248767B (en) Trimethoxyphenyl-benzaimidazole compounds for cancer treatment
HUS2400045I1 (hu) Delgocitinib alkalmazása krónikus kézekcéma kezelésére
HUE045764T2 (hu) Orvepitant krónikus légúti betegség kezelésére
PL3122349T3 (pl) Kompozycje do leczenia samotrawienia
ZA201901578B (en) Combinations including abx196 for the treatment of cancer
KR20180084983A (ko) 암의 치료를 위한 피리미도-피리미다지논의 용도
EP3145525A4 (en) Use of microperoxidases for the treatment of carboxyhemoglobinemia
IL252493A0 (en) Compounds for use in the prevention or treatment of cancer
SI3303486T1 (sl) Sestavek za površinsko obdelavo
IL255167A0 (en) Compounds for the treatment of cancer
ZA201704589B (en) Compounds for the treatment of cancer
PT3524255T (pt) Composição para o tratamento do acne
GB201511503D0 (en) Finishing treatment